Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Fidock

Showing results (151-160 of 303) with videos related to

Pageof 31
Sort By:
Molecular Biology and Evolution|April 18, 2014
Origin of robustness in generating drug-resistant malaria parasitesKrittikorn Kümpornsin, Charin Modchang, Adina Heinberg, et al.
The Lancet. Infectious Diseases|October 29, 2021
Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection studyJames S McCarthy, Özkan Yalkinoglu, Anand Odedra, et al.
The EMBO Journal|June 10, 2005
A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistanceViswanathan Lakshmanan, Patrick G Bray, Dominik Verdier-Pinard, et al.
Bioorganic & Medicinal Chemistry Letters|October 4, 2005
Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivativesJoel S Freundlich, John W Anderson, Dimitri Sarantakis, et al.
Journal of Medicinal Chemistry|March 5, 2021
3-Hydroxy-propanamidines, a New Class of Orally Active Antimalarials Targeting Plasmodium falciparumTanja C Knaab, Jana Held, Bjoern B Burckhardt, et al.
Nature Communications|August 25, 2023
Propensity of selecting mutant parasites for the antimalarial drug cabamiquineEva Stadler, Mohamed Maiga, Lukas Friedrich, et al.
Nature Communications|September 6, 2023
Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquineEva Stadler, Mohamed Maiga, Lukas Friedrich, et al.
ACS Infectious Diseases|October 31, 2018
Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265John White, Satish K Dhingra, Xiaoyi Deng, et al.
Molecular Microbiology|September 8, 2006
PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IXPatrick G Bray, Mathirut Mungthin, Ian M Hastings, et al.
The New England Journal of Medicine|September 27, 2023
Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in EritreaSelam Mihreteab, Lucien Platon, Araia Berhane, et al.
Pageof 31

Showing results (151-160 of 303) with videos related to

Sort By:
Pageof 31
Molecular Biology and Evolution|April 18, 2014
Origin of robustness in generating drug-resistant malaria parasitesKrittikorn Kümpornsin, Charin Modchang, Adina Heinberg, et al.
The Lancet. Infectious Diseases|October 29, 2021
Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection studyJames S McCarthy, Özkan Yalkinoglu, Anand Odedra, et al.
The EMBO Journal|June 10, 2005
A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistanceViswanathan Lakshmanan, Patrick G Bray, Dominik Verdier-Pinard, et al.
Bioorganic & Medicinal Chemistry Letters|October 4, 2005
Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivativesJoel S Freundlich, John W Anderson, Dimitri Sarantakis, et al.
Journal of Medicinal Chemistry|March 5, 2021
3-Hydroxy-propanamidines, a New Class of Orally Active Antimalarials Targeting Plasmodium falciparumTanja C Knaab, Jana Held, Bjoern B Burckhardt, et al.
Nature Communications|August 25, 2023
Propensity of selecting mutant parasites for the antimalarial drug cabamiquineEva Stadler, Mohamed Maiga, Lukas Friedrich, et al.
Nature Communications|September 6, 2023
Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquineEva Stadler, Mohamed Maiga, Lukas Friedrich, et al.
ACS Infectious Diseases|October 31, 2018
Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265John White, Satish K Dhingra, Xiaoyi Deng, et al.
Molecular Microbiology|September 8, 2006
PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IXPatrick G Bray, Mathirut Mungthin, Ian M Hastings, et al.
The New England Journal of Medicine|September 27, 2023
Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in EritreaSelam Mihreteab, Lucien Platon, Araia Berhane, et al.
Pageof 31